MaxCyte Financial Statements From 2010 to 2025

MXCT Stock  USD 3.18  0.08  2.45%   
MaxCyte financial statements provide useful quarterly and yearly information to potential MaxCyte investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on MaxCyte financial statements helps investors assess MaxCyte's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting MaxCyte's valuation are summarized below:
Gross Profit
31.5 M
Profit Margin
(1.06)
Market Capitalization
348.8 M
Enterprise Value Revenue
5.2161
Revenue
38.6 M
There are currently one hundred twenty fundamental ratios for MaxCyte that can be evaluated and compared over time across peers in the industry. All traders should check MaxCyte's last-minute fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 660.1 M in 2025. Enterprise Value is likely to gain to about 639.5 M in 2025

MaxCyte Total Revenue

23.45 Million

Check MaxCyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MaxCyte's main balance sheet or income statement drivers, such as Depreciation And Amortization of 5 M, Interest Expense of 138.6 K or Selling General Administrative of 31.2 M, as well as many indicators such as Price To Sales Ratio of 10.73, Dividend Yield of 0.0 or PTB Ratio of 2.22. MaxCyte financial statements analysis is a perfect complement when working with MaxCyte Valuation or Volatility modules.
  
Check out the analysis of MaxCyte Correlation against competitors.
For more information on how to buy MaxCyte Stock please use our How to Invest in MaxCyte guide.

MaxCyte Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets251.4 M239.5 M94.2 M
Slightly volatile
Short and Long Term Debt Total18.9 M18 M7.8 M
Slightly volatile
Other Current Liabilities4.6 M8.3 M3.8 M
Slightly volatile
Total Current Liabilities10.3 M15.8 M8.7 M
Slightly volatile
Property Plant And Equipment Net32 M30.5 M10 M
Slightly volatile
Current Deferred Revenue3.7 M5.3 MM
Slightly volatile
Accounts Payable1.5 M1.4 M1.8 M
Very volatile
Cash18.9 M27.9 M15.3 M
Slightly volatile
Non Current Assets Total71.2 M67.8 M17.6 M
Slightly volatile
Cash And Short Term Investments77.5 M154.5 M62.3 M
Slightly volatile
Net Receivables4.4 M4.7 M3.6 M
Slightly volatile
Common Stock Shares Outstanding70.5 M104.8 M61.9 M
Slightly volatile
Liabilities And Stockholders Equity251.4 M239.5 M94.2 M
Slightly volatile
Non Current Liabilities Total18.3 M17.4 M7.2 M
Slightly volatile
Inventory9.4 M8.9 M3.8 M
Slightly volatile
Other Current Assets1.9 M3.6 M1.5 M
Slightly volatile
Total Liabilities18.4 M33.2 M15.2 M
Slightly volatile
Total Current Assets88 M171.7 M70.8 M
Slightly volatile
Short Term Debt786.3 K864 K1.1 M
Slightly volatile
Common Stock590.5 K1.1 M473.1 K
Slightly volatile
Other Stockholder Equity249.3 M422 M164.2 M
Slightly volatile
Other Liabilities1.6 M1.5 M664.2 K
Slightly volatile
Net Tangible Assets306.7 M292.1 M99.1 M
Slightly volatile
Long Term Debt5.2 M5.7 M4.6 M
Slightly volatile
Common Stock Total Equity807.8 K1.2 M686.2 K
Slightly volatile
Net Invested Capital144.9 M206.3 M85.7 M
Slightly volatile
Property Plant And Equipment Gross46.3 M44.1 M11.7 M
Slightly volatile
Short and Long Term Debt680.7 K765.8 K834.9 K
Slightly volatile
Non Current Liabilities Other260.3 K274 K437.9 K
Pretty Stable
Net Working Capital124.8 M155.9 M74.7 M
Slightly volatile
Property Plant Equipment28.6 M27.3 M8.6 M
Slightly volatile
Short Term Investments108.8 M126.6 M51.7 M
Slightly volatile
Capital Stock941.9 K1.1 M690.2 K
Slightly volatile
Other Assets976.9 K930.4 K263.4 K
Slightly volatile
Capital Surpluse421.9 M449.4 M385.5 M
Slightly volatile

MaxCyte Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And AmortizationM4.8 M1.3 M
Slightly volatile
Interest Expense138.6 K145.9 K410.7 K
Pretty Stable
Selling General Administrative31.2 M29.7 M11.1 M
Slightly volatile
Selling And Marketing Expenses28 M26.7 M10.1 M
Slightly volatile
Total Revenue23.4 M38.6 M19.4 M
Slightly volatile
Gross Profit20.6 M31.5 M17 M
Slightly volatile
Other Operating Expenses94.3 M89.8 M36.2 M
Slightly volatile
Research Development13 M22.2 M10.7 M
Slightly volatile
Cost Of Revenue7.5 M7.1 M2.7 M
Slightly volatile
Total Operating Expenses86.9 M82.7 M33.5 M
Slightly volatile
Reconciled DepreciationM4.8 M1.3 M
Slightly volatile
Interest Income10.6 M10.1 M2.3 M
Slightly volatile

MaxCyte Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation13.7 M13.1 M4.2 M
Slightly volatile
Begin Period Cash Flow48.8 M46.5 M15.7 M
Slightly volatile
DepreciationM4.8 M1.3 M
Slightly volatile
Capital Expenditures2.8 M1.7 M2.2 M
Slightly volatile
End Period Cash Flow18.9 M27.9 M15.3 M
Slightly volatile
Change To Netincome14.4 M13.7 M4.5 M
Slightly volatile
Change To Liabilities751.1 K790.6 K1.1 M
Pretty Stable
Sale Purchase Of Stock436.1 K459 K180 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio10.7311.291965.6428
Slightly volatile
Days Sales Outstanding53.2644.241963.0228
Pretty Stable
Stock Based Compensation To Revenue0.360.33870.1174
Slightly volatile
Capex To Depreciation0.330.34471.6901
Slightly volatile
EV To Sales10.4911.036965.3572
Slightly volatile
Inventory Turnover0.960.79650.9721
Slightly volatile
Days Of Inventory On Hand375458433
Slightly volatile
Payables Turnover5.495.22832.9744
Slightly volatile
Sales General And Administrative To Revenue0.810.76870.4489
Slightly volatile
Research And Ddevelopement To Revenue0.420.57540.5081
Slightly volatile
Capex To Revenue0.05820.04270.0632
Slightly volatile
Cash Per Share1.551.47340.7439
Slightly volatile
Days Payables Outstanding66.3269.8127393
Slightly volatile
Income Quality0.80.67250.7797
Slightly volatile
Current Ratio11.4310.88335.5688
Slightly volatile
Receivables Turnover6.558.25016.2638
Slightly volatile
Capex Per Share0.02260.01570.0245
Slightly volatile
Revenue Per Share0.250.36840.2782
Slightly volatile
Interest Debt Per Share0.0960.1720.1106
Slightly volatile
Debt To Assets0.07150.07530.351
Slightly volatile
Operating Cycle428502496
Slightly volatile
Days Of Payables Outstanding66.3269.8127393
Slightly volatile
Ebt Per Ebit1.230.80191.1095
Slightly volatile
Total Debt To Capitalization0.07640.08041.009
Slightly volatile
Quick Ratio10.8310.31825.2348
Slightly volatile
Net Income Per E B T1.10.971.0251
Slightly volatile
Cash Ratio1.261.76761.4163
Slightly volatile
Days Of Inventory Outstanding375458433
Slightly volatile
Days Of Sales Outstanding53.2644.241963.0228
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio0.991.05981.1967
Slightly volatile
Fixed Asset Turnover1.21.267616.988
Slightly volatile
Debt Ratio0.07150.07530.351
Slightly volatile
Price Sales Ratio10.7311.291965.6428
Slightly volatile
Asset Turnover0.150.16130.9067
Slightly volatile
Gross Profit Margin0.970.81620.8782
Slightly volatile

MaxCyte Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap660.1 M436.2 M826.1 M
Slightly volatile
Enterprise Value639.5 M426.3 M791.2 M
Slightly volatile

MaxCyte Fundamental Market Drivers

Cash And Short Term Investments154.5 M

MaxCyte Upcoming Events

20th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About MaxCyte Financial Statements

MaxCyte shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although MaxCyte investors may analyze each financial statement separately, they are all interrelated. The changes in MaxCyte's assets and liabilities, for example, are also reflected in the revenues and expenses on on MaxCyte's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue5.3 M3.7 M
Total Revenue38.6 M23.4 M
Cost Of Revenue7.1 M7.5 M
Stock Based Compensation To Revenue 0.34  0.36 
Sales General And Administrative To Revenue 0.77  0.81 
Research And Ddevelopement To Revenue 0.58  0.42 
Capex To Revenue 0.04  0.06 
Revenue Per Share 0.37  0.25 
Ebit Per Revenue(1.33)(1.26)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for MaxCyte Stock Analysis

When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.